The Financial

BASAGLAR (insulin glargine injection 100 units/mL), A Long-Acting Basal Insulin, Is Now Available in U.S.

The FINANCIAL — Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. announced on December 15 that BASAGLAR (insulin glargine injection 100 units/mL) is available by prescription in ...
The Indianapolis Star

Lilly, Sanofi reach insulin deal

Eli Lilly and Co. has negotiated the right to market a knockoff version of the world's top-selling insulin, Lantus. The deal opens the door for Lilly and its German partner, Boehringer Ingelheim, to ...
FiercePharma

FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim's Basaglar™ (insulin glargine injection)

INDIANAPOLIS and RIDGEFIELD, Conn., Aug. 18, 2014 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today granted tentative approval for Basaglar™ (insulin glargine injection), which is ...
The Financial

FDA Approves Basaglar (insulin glargine injection), a Long-Acting Insulin Treatment

The FINANCIAL — Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) on December 16 announced that the U.S. Food and Drug Administration (FDA) granted approval for Basaglar ...
The Korea Herald

Basaglar challenges Sanofi’s insulin drug Lantus

Eli Lilly and Boehringer Ingelheim launched Basaglar, a biosimilar referencing Sanofi’s blockbuster insulin drug Lantus, in South Korea on Thursday, intent on challenging the original drug’s dominance ...